Back to top

Mesoblast Advances Rexlemestrocel???L BLA for High???Risk LVAD Heart Failure Patients

An update from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast has received a U.S. FDA Biologics License Application filing number and ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: